What You Need to Know
BiomX’s phase 2 trial demonstrated that BX211, an investigational phage therapy, was safe, well-tolerated, and showed a clinical benefit in reducing ulcer size for patients with diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus.
Despite its long history, phage therapy has been largely overlooked in Western medicine. However, with rising antibiotic resistance, there is renewed interest in its potential.
BiomX plans to move forward with a phase 2/3 study, pending FDA feedback, to further evaluate BX211’s efficacy and potential approval as a treatment option for DFO.